Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Prostate cancer overdiagnosis and overtreatment.

Klotz L.

Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi: 10.1097/MED.0b013e328360332a. Review.

PMID:
23609043
2.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
3.

Active surveillance for prostate cancer: overview and update.

Klotz L.

Curr Treat Options Oncol. 2013 Mar;14(1):97-108. doi: 10.1007/s11864-012-0221-5. Review.

PMID:
23318986
4.

Overdiagnosis and overtreatment of prostate cancer.

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. Review.

5.

Active surveillance: patient selection.

Klotz L.

Curr Opin Urol. 2013 May;23(3):239-44. doi: 10.1097/MOU.0b013e32835f8f6b. Review.

PMID:
23548978
6.

Active surveillance for prostate cancer: a review.

Klotz L.

Curr Urol Rep. 2010 May;11(3):165-71. doi: 10.1007/s11934-010-0110-z. Review.

PMID:
20425623
7.

Cancer overdiagnosis and overtreatment.

Klotz L.

Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa. Review.

PMID:
22472510
8.

Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.

Makovey I, Stephenson AJ, Haywood S.

Curr Urol Rep. 2013 Jun;14(3):168-73. doi: 10.1007/s11934-013-0318-9.

PMID:
23568623
9.

Active surveillance versus radical treatment for favorable-risk localized prostate cancer.

Klotz L.

Curr Treat Options Oncol. 2006 Sep;7(5):355-62. Review.

PMID:
16904052
10.

Active surveillance: the Canadian experience.

Klotz L.

Curr Opin Urol. 2012 May;22(3):222-30. doi: 10.1097/MOU.0b013e328352598c. Review.

PMID:
22453335
11.

Overdetection in screening for prostate cancer.

Hugosson J, Carlsson S.

Curr Opin Urol. 2014 May;24(3):256-63. doi: 10.1097/MOU.0000000000000054. Review.

PMID:
24670870
12.

Screening, early detection, and treatment of prostate cancer: a European view.

Schröder FH.

Urology. 1995 Sep;46(3 Suppl A):62-70. Review.

PMID:
7653022
13.

MRI and surveillance.

Ouzzane A, Puech P, Villers A.

Curr Opin Urol. 2012 May;22(3):231-6. doi: 10.1097/MOU.0b013e328351dcf7. Review.

PMID:
22388665
14.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

15.

Early detection, PSA screening, and management of overdiagnosis.

Borza T, Konijeti R, Kibel AS.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1091-110, vii. doi: 10.1016/j.hoc.2013.08.002. Epub 2013 Sep 18. Review.

PMID:
24188254
16.

Active surveillance: the Canadian experience with an "inclusive approach".

Klotz L.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):234-41. doi: 10.1093/jncimonographs/lgs042.

17.

Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Klotz L.

Curr Urol Rep. 2012 Apr;13(2):153-9. doi: 10.1007/s11934-012-0242-4. Review.

PMID:
22477615
18.

Overdiagnosis of prostate cancer.

Sandhu GS, Andriole GL.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):146-51. doi: 10.1093/jncimonographs/lgs031.

19.

[PSA-based screening for prostate cancer: a comparative analysis].

Cao WL, Sun FK.

Zhonghua Nan Ke Xue. 2013 Jun;19(6):559-62. Review. Chinese.

PMID:
23862239
20.

Active surveillance for prostate cancer: a review.

Klotz L.

Arch Esp Urol. 2011 Oct;64(8):806-14. Review. English, Spanish.

PMID:
22052761
Items per page

Supplemental Content

Write to the Help Desk